Lawrence Miller, Apnimed CEO
Apnimed, a late-stage sleep apnea biotech, eyes IPO in the second half
Apnimed, which has a novel sleep apnea drug in Phase III, is considering a potential IPO in the second half of this year even as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
